Cargando…
Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro
Cardiovascular disease has become the primary disease that threatens human health and is considered the leading cause of death. Cardiac remodeling, which is associated with cardiovascular disease, mainly manifests as cardiac hypertrophy, fibrosis, inflammation, and oxidative stress. Farrerol plays a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846078/ https://www.ncbi.nlm.nih.gov/pubmed/36686707 http://dx.doi.org/10.3389/fphar.2022.1079251 |
_version_ | 1784871075010576384 |
---|---|
author | He, Jian Xu, Dengyue Wang, Lu Yu, Xiaohong |
author_facet | He, Jian Xu, Dengyue Wang, Lu Yu, Xiaohong |
author_sort | He, Jian |
collection | PubMed |
description | Cardiovascular disease has become the primary disease that threatens human health and is considered the leading cause of death. Cardiac remodeling, which is associated with cardiovascular disease, mainly manifests as cardiac hypertrophy, fibrosis, inflammation, and oxidative stress. Farrerol plays an important role in treating conditions such as inflammation, endothelial injury and tumors, and we speculated that Farrerol may also play an important role in mitigating cardiac hypertrophy and remodeling. We established a model of myocardial remodeling using Angiotensin II (Ang II) with concurrent intraperitoneal injection of Farrerol as an intervention. We used cardiac ultrasound, immunohistochemistry, Immunofluorescence, Wheat Germ Agglutinin, Dihydroethidium, Western Blot, qPCR and other methods to detect the role of Farrerol in cardiac remodeling. The results showed that Farrerol inhibited Ang II-induced cardiac hypertrophy; decreased the ratio of heart weight to tibia length in mice; reduced inflammation, fibrosis, and oxidative stress; and reduced the size of cardiomyocytes in vivo. Farrerol inhibited Ang II-induced cardiomyocyte hypertrophy, levels of oxidative stress, and the proliferation and migration of fibroblast in vitro. Our results revealed that Farrerol could inhibit Ang II-induced cardiac remodeling. Farrerol may therefore be a candidate drug for the treatment of myocardial remodeling. |
format | Online Article Text |
id | pubmed-9846078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98460782023-01-19 Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro He, Jian Xu, Dengyue Wang, Lu Yu, Xiaohong Front Pharmacol Pharmacology Cardiovascular disease has become the primary disease that threatens human health and is considered the leading cause of death. Cardiac remodeling, which is associated with cardiovascular disease, mainly manifests as cardiac hypertrophy, fibrosis, inflammation, and oxidative stress. Farrerol plays an important role in treating conditions such as inflammation, endothelial injury and tumors, and we speculated that Farrerol may also play an important role in mitigating cardiac hypertrophy and remodeling. We established a model of myocardial remodeling using Angiotensin II (Ang II) with concurrent intraperitoneal injection of Farrerol as an intervention. We used cardiac ultrasound, immunohistochemistry, Immunofluorescence, Wheat Germ Agglutinin, Dihydroethidium, Western Blot, qPCR and other methods to detect the role of Farrerol in cardiac remodeling. The results showed that Farrerol inhibited Ang II-induced cardiac hypertrophy; decreased the ratio of heart weight to tibia length in mice; reduced inflammation, fibrosis, and oxidative stress; and reduced the size of cardiomyocytes in vivo. Farrerol inhibited Ang II-induced cardiomyocyte hypertrophy, levels of oxidative stress, and the proliferation and migration of fibroblast in vitro. Our results revealed that Farrerol could inhibit Ang II-induced cardiac remodeling. Farrerol may therefore be a candidate drug for the treatment of myocardial remodeling. Frontiers Media S.A. 2023-01-04 /pmc/articles/PMC9846078/ /pubmed/36686707 http://dx.doi.org/10.3389/fphar.2022.1079251 Text en Copyright © 2023 He, Xu, Wang and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology He, Jian Xu, Dengyue Wang, Lu Yu, Xiaohong Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro |
title | Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro
|
title_full | Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro
|
title_fullStr | Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro
|
title_full_unstemmed | Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro
|
title_short | Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro
|
title_sort | farrerol prevents angiotensin ii-induced cardiac remodeling in vivo and in vitro |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846078/ https://www.ncbi.nlm.nih.gov/pubmed/36686707 http://dx.doi.org/10.3389/fphar.2022.1079251 |
work_keys_str_mv | AT hejian farrerolpreventsangiotensiniiinducedcardiacremodelinginvivoandinvitro AT xudengyue farrerolpreventsangiotensiniiinducedcardiacremodelinginvivoandinvitro AT wanglu farrerolpreventsangiotensiniiinducedcardiacremodelinginvivoandinvitro AT yuxiaohong farrerolpreventsangiotensiniiinducedcardiacremodelinginvivoandinvitro |